Table 2 Univariate and Multivariate Analysis of Factors Associated with Time To Recurrence and Overall Survival in Cohort I HCC Patients (n = 280) and Cohort II HCC Patients (n = 210)

 Age

0.994 (0.979–1.009)

0.427

0.989 (0.973–1.004)

0.152

 Sex (female versus male)

0.861 (0.574–1.293)

0.861

0.902 (0.592–1.373)

0.630

 Serum AFP (≤20 versus > 20 ng/ml)

1.418 (0.927–2.170)

0.108

1.301 (0.849–1.994)

0.227

 Virus infection (no versus yes)

0.986 (0.796–1.222)

0.896

1.002 (0.808–1.243)

0.986

 Cirrhosis (absent versus present)

1.039 (0.741–1.456)

0.825

1.132 (0.797–1.606)

0.489

 Child-pugh score (A versus B)

1.254 (0.835–1.884)

0.274

1.247 (0.824–1.887)

0.296

 Tumor number (single versus multiple)

2.596 (1.903–3.540)

< 0.001

0.343 (0.250–0.470)

< 0.001

 Maximal tumor size (≤5 versus > 5 cm)

0.583 (0.482–0.706)

0.013

0.696 (0.509–0.951)

0.023

 Tumor encapsulation (absent versus present)

0.341 (0.248–0.469)

< 0.001

3.065 (2.221–4.230)

< 0.001

 Microvascular invasion (absent versus present)

2.338 (1.720–3.179)

< 0.001

0.405 (0.296–0.554)

< 0.001

 Tumor differentiation (I-II versus III-IV)

0.295 (0.241–0.361)

< 0.001

0.317 (0.229–0.439)

< 0.001

 TNM stage (I-II versus III)

3.032 (2.193–4.191)

< 0.001

0.145 (0.102–0.205)

< 0.001

 CTH (negative versus positive)

6.289 (4.444–8.901)

< 0.001

3.733 (2.629–5.299)

< 0.001

 Tumor number (single versus multiple)

0.707 (0.473–1.057)

0.091

0.616 (0.413–0.920)

0.018

 Maximal tumor size (≤5 versus > 5 cm)

1.050 (0.749–1.471)

0.778

1.085 (0.766–1.537)

0.645

 Tumor encapsulation (absent versus present)

1.448 (0.937–2.238)

0.096

1.392 (0.889–2.178)

0.148

 Microvascular invasion (absent versus present)

0.674 (0.469–0.968)

0.033

0.631 (0.436–0.912)

0.014

 Tumor differentiation (I-II versus III-IV)

0.858 (0.514–1.435)

0.560

0.933 (0.548–1.587)

0.798

 TNM stage (I-II versus III)

0.357 (0.197–0.645)

0.001

0.335 (0.184–0.611)

< 0.001

 CTH (negative versus positive)

2.759 (1.941–3.922)

< 0.001

2.969 (2.054–4.293)

< 0.001

 Cohort II (n = 210)

 Clinical Variables

HR(95%CI)

P value

HR(95%CI)

P value

 Age

0.987 (0.970–1.004)

0.122

0.985 (0.968–1.002)

0.076

 Sex (female versus male)

0.769 (0.499–1.184)

0.232

0.722 (0.468–1.115)

0.722

 Serum AFP (≤20 versus > 20 ng/ml)

1.199 (0.788–1.825)

0.397

1.248 (0.809–1.927)

0.316

 Virus infection (no versus yes)

0.959 (0.700–1.313)

0.792

0.923 (0.669–1.275)

0.628

 Cirrhosis (absent versus present)

0.873 (0.595–1.282)

0.489

0.860 (0.583–1.271)

0.450

 Child-pugh score (A versus B)

0.973 (0.649–1.460)

0.896

0.981 (0.649–1.482)

0.927

 Tumor number (single versus multiple)

1.984 (1.398–2.817)

< 0.001

0.484 (0.338–0.691)

< 0.001

 Maximal tumor size (≤5 versus > 5 cm)

1.328 (0.934–1.888)

0.114

0.705 (0.491–1.012)

0.058

 Tumor encapsulation (absent versus present)

0.354 (0.249–0.505)

< 0.001

3.085 (2.148–4.431)

< 0.001

 Microvascular invasion (absent versus present)

2.319 (1.629–3.301)

< 0.001

0.389 (0.271–0.559)

< 0.001

 Tumor differentiation (I-II versus III-IV)

2.128 (1.422–3.184)

< 0.001

0.431 (0.287–0.647)

< 0.001

 TNM stage (I-II versus III)

7.507 (4.967–11.345)

< 0.001

0.124 (0.082–0.188)

< 0.001

 CTH (negative versus positive)

0.261 (0.178–0.382)

< 0.001

4.409 (2.950–6.588)

< 0.001

 Tumor number (single versus multiple)

1.011 (0.667–1.534)

0.958

0.986 (0.638–1.523)

0.949

 Maximal tumor size (≤5 versus > 5 cm)

0.856 (0.510–1.436)

0.556

0.787 (0.462–1.340)

0.377

 Tumor encapsulation (absent versus present)

1.679 (1.012–2.786)

0.045

1.636 (0.976–2.742)

0.062

 Microvascular invasion (absent versus present)

1.111 (0.660–1.871)

0.693

1.000 (0.591–1.694)

1.000

 Tumor differentiation (I-II versus III-IV)

0.851 (0.547–1.324)

0.475

0.778 (0.499–1.212)

0.267

 TNM stage (I-II versus III)

0.173 (0.094–0.321)

0.001

0.172 (0.091–0.323)

< 0.001

 CTH (negative versus positive)

3.403 (2.243–5.164)

< 0.001

3.816 (2.467–5.903)

< 0.001